Clinical Trial

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of dalpiciclib combined with pyrotinib as second-line therapy in patients with advanced esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT06684600
Lead Sponsor Peking University
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 35 participants
Start Date 2024-11-01
Primary Completion 2025-10-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-12